MOSCOW, May 6. /TASS/. A one-component COVID-19 vaccine dubbed Sputnik Light has been registered in Russia, the Russian Direct Investment Fund (RDIF) informs. The Russian Ministry of Health, the Gamaleya Research Center and RDIF announce the registration of the one-component vaccine Sputnik Light against the novel coronavirus infection. Sputnik Light is the first component of the Sputnik V coronavirus vaccine, the message says.
The efficacy of the one-component Sputnik Light vaccine was 79.4% starting from the 28th day after immunization. Its efficiency at nearly 80% outperforms many vaccines, requiring two jabs.
The evaluation of the efficacy was based on the data of those Russians, who received only one jab within the program of the sweeping civilian vaccination drive and those who did not receive the second jab due to any reason whatsoever from December 2, 2020 to April 15, 2021.
Moderna s recognition as best coronavirus vaccine comes as an economic and political move of the World Congress, Alexander Gintsburg, director of the Gamaleya Research Center for Electrochemistry said, RIA Novosti reports. The number of deaths caused by RNA-containing vaccines, such as Moderna, considerably exceeds the number of deaths from the AstraZeneca vaccine, the head of the center, the developer of the Russian Sputnik V vaccine against COVID-19 told reporters. The price of the issue is about $100 billion.
Recognizing Sputnik V means supporting the Russian Federation, and the congress took place, let me remind you, in Washington,” Gintsburg added.
Moderna s drug won Best COVID Vaccine at the 2021 World Vaccine Congress. Sputnik V and AstraZeneca were shortlisted for the nomination. The vaccine from Pfizer and BioNTech was also highly praised. The selection criteria for the winners are unknown.
Sputnik Light Effective in Re-Vaccination, Combination With Other Vaccines - Developer Thu 06th May 2021 | 05:20 PM
MOSCOW (UrduPoint News / Sputnik - 06th May, 2021) Russia s single-dose Sputnik Light COVID-19 vaccine is effective in initial vaccination, re-vaccination and can be used to boost the efficacy if administered in combination with other vaccines, Alexander Gintsburg, director of the Gamaleya Research Center for Epidemiology and Microbiology of the Russian Health Ministry, said.
The Russian Health Ministry, the Gamaleya research center and the Russian Direct Investment Fund (RDIF) previously announced that Sputnik Light had received authorization for use in Russia. Sputnik Light offers strong value in initial vaccination and re-vaccination, as well as boosting efficacy when taken in combination with other vaccines, Gintsburg said as quoted in a RDIF press release.
April 27, 2021
On April 15, Gavi, the Vaccine Alliance, and the U.S. government co-hosted a high-level meeting centered around the theme of “One World Protected” to launch a fundraising campaign for the COVAX Advance Market Commitment (AMC). The COVAX AMC is a financing mechanism intended to make Covid-19 vaccines available at low cost for 92 lower- and lower-middle income countries with an annual gross national income per capita of less than $4,000. An adaptation of an earlier financing model used successfully to incentivize the production and distribution of new vaccines for pneumococcal disease, the COVAX AMC works by assuring manufacturers of a commitment to purchase a large quantity of vaccines and then uses donor funds to make them available at a reduced price per dose for lower and lower-middle income countries.
Gamaleya Center patents intranasal coronavirus vaccine interfax.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from interfax.com Daily Mail and Mail on Sunday newspapers.